Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 3.23 Mil Enterprise Value: -7.02 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 57/100

Q1 2022 Matinas BioPharma Holdings Inc Earnings Call Transcript

May 12, 2022 / 12:30PM GMT
Release Date Price: €29.5 (-2.90%)
Operator

Welcome to the Matinas BioPharma First Quarter 2022 Results Conference Call. . (Operator Instructions)

I would now like to turn the conference over to Peter Vozzo, Investor Relations representative for Matinas BioPharma. You may begin.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you. Good morning, everyone, and thank you for joining the Matinas BioPharma First Quarter 2022 Results Conference Call. Earlier this morning, we issued a press release with our financial results along with business updates. The release is available on the Matinas BioPharma website under the Investors section.

Speaking on today's call will be Jerry Jabbour, Chief Executive Officer; Dr. Terri Matkovits, Chief Development Officer; Dr. Terry Ferguson, Chief Financial Officer -- Chief Medical Officer, sorry; and Keith Kucinski, Chief Financial Officer. We also have Mr. Thomas Hoover, Chief Business Officer, who will be available to answer questions during our Q&A session.

At this time, I would like to remind our listeners that remarks made during this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot